Healing & Recovery

BPC-157

Also known as: Body Protection Compound-157, Pentadecapeptídeo gástrico

Molecular Identifiers

Molecular Formula

C62H98N16O22

CAS Number

137525-51-0

PubChem CID

9941957

Molecular Weight

1419.53 Da

Overview

Synthetic pentadecapeptide derived from a human gastric protective protein (BPC). Composed of 15 amino acids with the sequence GEPPPGKPADDAGLV, with a molecular weight of 1,419.53 Da. Stable in gastric juice and does not require a carrier for biological activity.

The main clinical interest around BPC-157 is its regenerative effect on soft tissues — tendons, ligaments, gastric and intestinal mucosa — and its systemic anti-inflammatory profile. Preclinical studies show accelerated healing, intestinal barrier protection, and nitric oxide modulation, which explains its widespread use in sports medicine and in cases of dysbiosis or gastrointestinal injury.

BPC-157 currently has no regulatory approval from any major agency (FDA, EMA, ANVISA). It is most often dispensed by compounding pharmacies as off-label use, in 4–8 week protocols with subcutaneous administration near the injury site. WADA lists it as a substance prohibited in sports competition.

It was characterized in the early 1990s by the Croatian research group led by Predrag Sikiric, from a stable fraction of a protective protein extracted from human gastric juice. Decades of preclinical research have consolidated its safety profile in animals, but human clinical trials remain limited.

Among regenerative peptides it is most often compared to TB-500: while TB-500 (a synthetic fragment of thymosin β-4) acts predominantly via G-actin and cell migration, with a more systemic profile and a long half-life, BPC-157 has a more localized effect, prominent activity on the gastrointestinal axis, and more frequent dosing. The two are commonly stacked in recovery protocols because their mechanisms are complementary.

Sequence (1 letter): GEPPPGKPADDAGLV

Extended notation: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Half-life

~4 hours

Administration Route

Subcutaneous or oral

Mechanism of Action

VEGFR2 receptor upregulation and angiogenesis promotion
Nitric oxide (NO) system modulation
Interaction with the dopaminergic and GABAergic systems
Promotion of GH receptor expression in tendons
Cytoprotective effect on the gastrointestinal mucosa

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter	Value
Dose	250-500 mcg per injection
Frequency	1-2 times daily
Timing	Morning and/or evening
Duration	4-8 weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

Mild nausea (rare)
Injection site pain
Dizziness (rare)

Product Properties

Purity	>99%
Appearance	White lyophilized powder
Solubility	Soluble in water
Source	Solid-phase peptide synthesis (SPPS)
Storage	Lyophilized: -20°C for up to 2 years, 2-8°C for up to 12 months, room temperature for up to 90 days. Reconstituted: 2-8°C for up to 4 weeks. Stable in acidic solutions. Protect from light.